Skip to main content
Caplight Logo









Recepta Biopharma

Recepta Biopharma

Private
São PauloHealthcare & Life Scienceshttp://www.receptabio.com.br/

Last Round

VC Round

Jul 26, 2012

Total Funding Raised

$3.5M

Company Overview

Recepta Biopharma is a biotechnology company that researches and develops monoclonal antibodies and peptides for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

monoclonal antibodiesoncology drug developmentbiotech R&Dclinical-stage biotechdrug licensingsmall moleculescancer therapybiopharmadrug discoveryintellectual propertyclinical trialspharma partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Recepta Biopharma Comparables

Compare Recepta Biopharma with similar companies based on industry and business-model similarity.

Recepta Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ImunoTera Soluções Terapêuticas
74%
Andes Biotechnologies
74%
Celluris
68%

Recepta Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJul 26, 2012
GrantJun 1, 2007

Recepta Biopharma Investors

Notable investors and investment history

Recepta Biopharma investors
InvestorRounds
Financiadora de Estudos e ProjetosVC Round, Grant
FAPESPGrant
BNDES Participações S.A.VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Monthly visitors increased 33% MoM, reaching 3.7K.

  • Jun 1, 2007

    Secured $3.16M in grant funding from Financiadora de Estudos e Projetos.

Recepta Biopharma Filings

Explore SEC and related filing metadata, where available.

Recepta Biopharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Recepta Biopharma's valuation, stock price, and market status.

Is Recepta Biopharma a public or private company?

Recepta Biopharma is a private company.

What is the current stock price of Recepta Biopharma?

Recepta Biopharma is a private company with no public stock price. No recent secondary market data is available.

How much is Recepta Biopharma worth (valuation)?

Valuation information for Recepta Biopharma is not publicly available.

Can I buy Recepta Biopharma stock?

Recepta Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Recepta Biopharma's last funding round?

Recepta Biopharma's most recent funding round was VC Round on July 26, 2012.

Who are the main investors in Recepta Biopharma?

Key investors in Recepta Biopharma include BNDES Participações S.A..

Will Recepta Biopharma IPO soon?

No public IPO plans have been announced for Recepta Biopharma.

How can I track Recepta Biopharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Recepta Biopharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSão Paulo
Employee Range10
Year Founded2006
Last FundingJul 26, 2012

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?